These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 2114832)
21. Tyrosinase immobilized magnetic nanobeads for the amperometric assay of enzyme inhibitors: application to the skin whitening agents. Sima VH; Patris S; Aydogmus Z; Sarakbi A; Sandulescu R; Kauffmann JM Talanta; 2011 Jan; 83(3):980-7. PubMed ID: 21147347 [TBL] [Abstract][Full Text] [Related]
22. Azelaic acid has antimycotic properties in vitro. Brasch J; Christophers E Dermatology; 1993; 186(1):55-8. PubMed ID: 8435518 [TBL] [Abstract][Full Text] [Related]
23. 1-(2,4-Dihydroxyphenyl)-3-(2,4-dimethoxy-3-methylpheny)propane inhibits melanin synthesis by dual mechanisms. Niki Y; Yoshida M; Ando H; Wakamatsu K; Ito S; Harada N; Matsui MS; Yarosh DB; Ichihashi M J Dermatol Sci; 2011 Aug; 63(2):115-21. PubMed ID: 21680155 [TBL] [Abstract][Full Text] [Related]
24. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Mastrofrancesco A; Ottaviani M; Aspite N; Cardinali G; Izzo E; Graupe K; Zouboulis CC; Camera E; Picardo M Exp Dermatol; 2010 Sep; 19(9):813-20. PubMed ID: 20545756 [TBL] [Abstract][Full Text] [Related]
25. Azelaic acid: mode of action at cellular and subcellular levels. Galhaup I Acta Derm Venereol Suppl (Stockh); 1989; 143():75-82. PubMed ID: 2475996 [TBL] [Abstract][Full Text] [Related]
26. Arbutin: mechanism of its depigmenting action in human melanocyte culture. Maeda K; Fukuda M J Pharmacol Exp Ther; 1996 Feb; 276(2):765-9. PubMed ID: 8632348 [TBL] [Abstract][Full Text] [Related]
27. The melanogenesis and mechanisms of skin-lightening agents--existing and new approaches. Gillbro JM; Olsson MJ Int J Cosmet Sci; 2011 Jun; 33(3):210-21. PubMed ID: 21265866 [TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy of products containing azelaic acid in melasma treatment. Mazurek K; Pierzchała E J Cosmet Dermatol; 2016 Sep; 15(3):269-82. PubMed ID: 27028014 [TBL] [Abstract][Full Text] [Related]
29. The stereospecific suicide inhibition of human melanoma thioredoxin reductase by 13-cis-retinoic acid. Schallreuter KU; Wood JM Biochem Biophys Res Commun; 1989 Apr; 160(2):573-9. PubMed ID: 2719682 [TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of arbutin on melanin biosynthesis of alpha-melanocyte stimulating hormone-induced hyperpigmentation in cultured brownish guinea pig skin tissues. Lim YJ; Lee EH; Kang TH; Ha SK; Oh MS; Kim SM; Yoon TJ; Kang C; Park JH; Kim SY Arch Pharm Res; 2009 Mar; 32(3):367-73. PubMed ID: 19387580 [TBL] [Abstract][Full Text] [Related]
31. Oxymetric and spectrophotometric study of the ascorbate oxidase activity shown by frog epidermis tyrosinase. Ramón Ros J; Rodríguez-López JN; Carlos Espín J; Varón R; García-Cánovas F Int J Biochem Cell Biol; 1996 Aug; 28(8):917-23. PubMed ID: 8811840 [TBL] [Abstract][Full Text] [Related]
32. Effect of dicarboxylic (C6 and C9) acids on a human squamous carcinoma cell line in culture. Pätzold HC; Breathnach AS; Robins EJ; Daridan ME; Bhasin YP; Ethridge LB; Nazzaro-Porro M; Passi S; Picardo M Histol Histopathol; 1989 Apr; 4(2):167-71. PubMed ID: 2520453 [TBL] [Abstract][Full Text] [Related]
33. Effect of L-carnitine on cultured murine melanoma cells exposed to azelaic acid. Ward BJ; Breathnach AS; Robins EJ; Bhasin YP; Ethridge L; Nazzaro-Porro M; Passi S J Invest Dermatol; 1986 Apr; 86(4):438-41. PubMed ID: 3745962 [TBL] [Abstract][Full Text] [Related]
34. An evaluation of the effectiveness of azelaic acid as a depigmenting and chemotherapeutic agent. Pathak MA; Ciganek ER; Wick M; Sober AJ; Farinelli WA; Fitzpatrick TB J Invest Dermatol; 1985 Sep; 85(3):222-8. PubMed ID: 4031538 [TBL] [Abstract][Full Text] [Related]
35. Hyperpigmentary disorders--mechanisms of action. Effect of azelaic acid on melanoma and other tumoral cells in culture. Breathnach AS; Robins EJ; Nazzaro-Porro M; Passi S; Picardo M Acta Derm Venereol Suppl (Stockh); 1989; 143():62-6. PubMed ID: 2672685 [TBL] [Abstract][Full Text] [Related]
36. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541 [TBL] [Abstract][Full Text] [Related]
37. A prodrug approach to enhance azelaic acid percutaneous availability. Al-Marabeh S; Khalil E; Khanfar M; Al-Bakri AG; Alzweiri M Pharm Dev Technol; 2017 Jun; 22(4):578-586. PubMed ID: 27346659 [TBL] [Abstract][Full Text] [Related]
38. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Nguyen QH; Bui TP Int J Dermatol; 1995 Feb; 34(2):75-84. PubMed ID: 7737781 [No Abstract] [Full Text] [Related]
39. Azelaic acid: its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. Bojar RA; Holland KT; Leeming JP; Cunliffe WJ J Appl Bacteriol; 1988 Jun; 64(6):497-504. PubMed ID: 2459099 [TBL] [Abstract][Full Text] [Related]
40. Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. Vereecken P; Heenen M Int J Clin Pract; 2002; 56(1):68-9. PubMed ID: 11831841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]